Orano Med, a biotechnology company developing Lead-212 (212Pb) targeted alpha therapy against cancer, and Orbit Discovery, a company discovering therapeutic peptide hits, have entered into a collaboration to discover specific peptide receptor radionuclide therapies (PRRT) against cancer cells and advance the development of novel radiopharmaceuticals. Under the terms of the agreement, Orbit will deploy […]